OmniAb, Inc. (OABI)
Nasdaq · Services-Commercial Physical & Biological Research · Services · CIK 1846253 · fiscal year ends in Dec
Closing price $5.23 on 29 Oct 2026; 52-week range $1.36 to $5.29.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $40.2M
- Revenue growth
- 90.6%
- Net income, last twelve months
- -$43.5M
- Earnings per share
- -$0.34
- Operating margin
- -115.9%
- Net margin
- -108.1%
- Free cash flow
- $2.4M
- Return on equity
- -17.4%
- Market value
- $762.8M
- Cash
- $22.9M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 145.9M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $18.7M | -$69.0M | -$64.8M | -$0.57 | -$37.0M | 10-K filed 4 Mar 2026 |
| FY2024 | 31 Dec 2024 | $26.4M | -$74.5M | -$62.0M | -$0.61 | -$41.5M | 10-K filed 18 Mar 2025 |
| FY2023 | 31 Dec 2023 | $34.2M | -$69.4M | -$50.6M | -$0.51 | $703.0K | 10-K filed 25 Mar 2024 |
| FY2022 | 31 Dec 2022 | $59.1M | -$26.6M | -$22.3M | -$0.26 | -$20.8M | 10-K filed 30 Mar 2023 |
| FY2021 | 31 Dec 2021 | $34.7M | -$35.6M | -$27.0M | -$0.33 | -$9.7M | 10-K filed 30 Mar 2023 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $4.0M | -$15.7M | -$0.12 |
| Q2 FY2026 | 30 Jun 2026 | $13.4M | -$5.9M | -$0.05 |
| Q1 FY2026 | 31 Mar 2026 | $14.4M | -$7.7M | -$0.06 |
| Q4 FY2025 | 31 Dec 2025 | $8.4M | -$14.2M | -$0.11 |
| Q3 FY2025 | 30 Sep 2025 | $2.2M | -$16.5M | -$0.14 |
| Q2 FY2025 | 30 Jun 2025 | $3.9M | -$15.9M | -$0.15 |
| Q1 FY2025 | 31 Mar 2025 | $4.2M | -$18.2M | -$0.17 |
| Q4 FY2024 | 31 Dec 2024 | $10.8M | -$13.1M | -$0.12 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| License and milestone revenue | $9.8M | 52.3% |
| Service revenue | $7.3M | 38.9% |
| Royalty revenue | $878.0K | 4.7% |
| xPloration revenue | $754.0K | 4.0% |
Company events
The newest 8-K filings of 43 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 6 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 13 Jul 2026 | 8-K | Leadership change | 5.02 |
| 18 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 7 May 2026 | 8-K | Results | 2.02, 9.01 |
| 4 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 30 Jan 2026 | 8-K | Bylaws or fiscal year change | 5.03, 9.01 |
| 4 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 25 Aug 2025 | 8-K | Material agreement, Share sale, Investor update | 1.01, 3.02, 7.01, 9.01 |
| 6 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 18 Jun 2025 | 8-K | Shareholder vote | 5.07 |
| 8 May 2025 | 8-K | Results | 2.02, 9.01 |
| 21 Apr 2025 | 8-K | Leadership change | 5.02 |
Every filing
The newest filings with the SEC of 148 held.
| Filed | Form | Period |
|---|---|---|
| 6 Aug 2026 | 10-Q | 30 Jun 2026 |
| 6 Aug 2026 | 8-K | 6 Aug 2026 |
| 13 Jul 2026 | 8-K | 13 Jul 2026 |
| 18 Jun 2026 | 8-K | 17 Jun 2026 |
| 7 May 2026 | 10-Q | 31 Mar 2026 |
| 7 May 2026 | 8-K | 7 May 2026 |
| 29 Apr 2026 | ARS | 31 Dec 2025 |
| 29 Apr 2026 | DEFA14A | – |
| 29 Apr 2026 | DEF 14A | 17 Jun 2026 |
| 4 Mar 2026 | 10-K | 31 Dec 2025 |
| 4 Mar 2026 | 8-K | 4 Mar 2026 |
| 30 Jan 2026 | 8-K | 30 Jan 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 7 Apr 2026 | Foehr Matthew W, President and CEO | Sale outside a trading plan | 19,244 | $1.49 | $28.7K | 4,420,492 | 7 Apr 2026 |
| 7 Apr 2026 | Gustafson Kurt A, Executive VP, Finance and CFO | Sale outside a trading plan | 6,913 | $1.49 | $10.3K | 261,483 | 7 Apr 2026 |
| 7 Apr 2026 | Berkman Charles S, Chief Legal Officer | Sale outside a trading plan | 7,157 | $1.49 | $10.7K | 399,085 | 7 Apr 2026 |
| 18 Feb 2026 | Berkman Charles S, Chief Legal Officer | Sale outside a trading plan | 9,673 | $1.71 | $16.5K | 392,700 | 18 Feb 2026 |
| 18 Feb 2026 | Gustafson Kurt A, Executive VP, Finance and CFO | Sale outside a trading plan | 9,301 | $1.71 | $15.9K | 268,851 | 18 Feb 2026 |
| 18 Feb 2026 | Foehr Matthew W, President and CEO | Sale outside a trading plan | 30,843 | $1.71 | $52.7K | 4,403,277 | 18 Feb 2026 |
| 17 Feb 2026 | Foehr Matthew W, President and CEO | Sale outside a trading plan | 20,754 | $1.70 | $35.3K | 4,375,787 | 17 Feb 2026 |
| 17 Feb 2026 | Gustafson Kurt A, Executive VP, Finance and CFO | Sale outside a trading plan | 6,828 | $1.70 | $11.6K | 259,402 | 17 Feb 2026 |
| 17 Feb 2026 | Berkman Charles S, Chief Legal Officer | Sale outside a trading plan | 6,990 | $1.70 | $11.9K | 383,623 | 17 Feb 2026 |
| 8 Dec 2025 | Berkman Charles S, Chief Legal Officer | Sale outside a trading plan | 8,044 | $1.96 | $15.8K | 377,071 | 9 Dec 2025 |
| 8 Dec 2025 | Gustafson Kurt A, Executive VP, Finance and CFO | Sale outside a trading plan | 23,922 | $1.96 | $46.9K | 252,688 | 9 Dec 2025 |
| 8 Dec 2025 | Foehr Matthew W, President and CEO | Sale outside a trading plan | 13,666 | $1.96 | $26.8K | 4,360,083 | 9 Dec 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 7 Apr 2026 | GUSTAFSON KURT A, Officer | 6,913 | $10.3K | 7 Apr 2026 |
| 7 Apr 2026 | Berkman Charles S, Officer | 7,157 | $10.6K | 7 Apr 2026 |
| 7 Apr 2026 | FOEHR MATTHEW W, Officer | 19,244 | $28.6K | 7 Apr 2026 |
| 17 Feb 2026 | Berkman Charles S, Officer | 6,891 | $11.7K | 17 Feb 2026 |
| 17 Feb 2026 | GUSTAFSON KURT A, Officer | 6,891 | $11.7K | 17 Feb 2026 |
| 17 Feb 2026 | FOEHR MATTHEW W, Officer | 20,483 | $34.8K | 17 Feb 2026 |
| 8 Dec 2025 | Berkman Charles S, Officer | 8,044 | $15.8K | 8 Dec 2025 |
| 8 Dec 2025 | FOEHR MATTHEW W, Officer | 13,666 | $26.8K | 8 Dec 2025 |
| 8 Dec 2025 | GUSTAFSON KURT A, Officer | 23,922 | $46.9K | 8 Dec 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 14 Aug 2026 | Whitefort Capital Management, LP | 13G amended | 7.1% | 10.2M |
| 10 Feb 2026 | Ash X LP | 13G amended | 8.5% | 12.3M |
| 14 Nov 2025 | Whitefort Capital Management, LP | 13G amended | 9.9% | 14.2M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 8.5M | +4.22% | 6.67 |
| 30 Sep 2026 | 8.2M | +15.05% | 6.75 |
| 15 Sep 2026 | 7.1M | +19.1% | 4.11 |
| 31 Aug 2026 | 6.0M | -4.19% | 1.85 |
| 14 Aug 2026 | 6.2M | +4.13% | 6.5 |
| 31 Jul 2026 | 6.0M | +2.04% | 17.65 |
| 15 Jul 2026 | 5.9M | +23.61% | 10.26 |
| 30 Jun 2026 | 4.8M | +1.21% | 6.37 |
Funds that hold it
From each fund's latest Form 13F.
148 funds held it at 30 Jun 2026: 77 added and 32 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Whitefort Capital Management, LP | 10,248,658 | $25.2M | -3,975,000 |
| BlackRock, Inc. | 8,897,490 | $21.9M | +790,609 |
| Nomura Holdings Inc. | 5,028,160 | $12.4M | +4,323,112 |
| Cadian Capital Management, LP | 4,211,821 | $10.4M | +54,692 |
| Vanguard Capital Management LLC | 3,852,356 | $9.5M | -141,296 |
| Geode Capital Management, LLC | 2,883,978 | $7.1M | -41,601 |
| Rice Hall James & Associates, LLC | 2,610,434 | $6.4M | +63,179 |
| Private Management Group Inc. | 2,344,770 | $5.8M | -84,396 |
| State Street Corp. | 2,133,549 | $5.2M | +66,406 |
| Dimensional Fund Advisors LP | 1,262,099 | $3.1M | -483,149 |
Peers
Companies in the same industry.
- IQVIA Holdings Inc. (IQV): revenue $17.3B, market value $45.3B
- Incyte Corp. (INCY): revenue $6.0B, market value $23.8B
- Medpace Holdings, Inc. (MEDP): revenue $2.8B, market value $18.9B
- Charles River Laboratories International, Inc. (CRL): revenue $4.0B, market value $18.0B
- ICON plc (ICLR): revenue $8.3B, market value $16.5B
- Absci Corp. (ABSI): revenue $1.6M, market value $2.1B
- NRC Health (NRC): revenue $140.0M, market value $520.7M